Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure - report from AHA 2025

Professor Stephen Nicholls shares his insights on the pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial at AHA Scientific Sessions 2025.

Video: https://medicaldigest.org/scientific-contents/interview:once-weekly-tirzepatide-versus-dulaglutide-heart-failure-outcomes-patients-type-2-diabetes-ascvd-and-history-heart-failure